Antimicrobial peptides in the real world: Implications for cystic fibrosis

European Respiratory Journal

Volumn 29, Issue 4, 2007, Pages 617-618

  Hiemstra, P S ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA DEFENSIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; POLYPEPTIDE ANTIBIOTIC AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CYSTIC FIBROSIS; EDITORIAL; HOST RESISTANCE; HUMAN; INFECTION SENSITIVITY; INNATE IMMUNITY; MUCOCILIARY CLEARANCE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PSEUDOMONAS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CYSTIC FIBROSIS; EPITHELIUM; HUMANS; INFLAMMATION; LUNG; PSEUDOMONAS;

EID: 34147129776     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00017007     Document Type: Editorial

References (13)

1. Randell SH, Boucher RC, University of North Carolina Virtual Lung Group. Effective mucus clearance is essential for respiratory health. Am J Respir Cell Mol Biol 2006; 35:20-28.
2. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999; 103: 303-307.
3. Bals, R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23: 327-333.
4. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 299-236.
5. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human β-defensin-1 is a salt-sensitive antibiotic in the lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-560.
6. Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM. Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol 2001; 25: 21-25.
7. Taggart CC, Greene CM, Smith SG, et al. Inactivation of human beta-defensins 2 and 3 by elastolytic cathepsins. J Immunol 2003; 171: 931-937.
8. Bucki R, Byfield FJ, Janmey PA. Release of the anti-microbial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 2007; 29: 624-632.
9. Tjabringa GS, Rabe KF, Hiemstra PS. The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung. Pulm Pharmacol Ther 2005; 18: 321-327.
10. Felgentreff K, Beisswenger C, Griese M, Gulder T, Bringmann G, Bals R. The antimicrobial peptide cathelicidin interacts with airway mucus. Peptides 2006; 27: 3100-3106.
11. Herasimenka Y, Benincasa M, Mattiuzzo M, Cescutti P, Gennaro R, Rizzo R. Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides 2005; 26: 1127-1132.
12. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003; 28: 738-745.
13. Moskwa P, Lorentzen D, Excoffon KJ, et al. A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med 2007; 175: 174-183.